La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Perspective Therapeutics Croissance future

Future contrôle des critères 2/6

Perspective Therapeutics devrait augmenter ses bénéfices et ses revenus de 13.7% et de 79.6% par an respectivement, tandis que le BPA devrait croître de croître de 20.1% par an.

Informations clés

9.1%

Taux de croissance des bénéfices

20.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	81.3%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	25 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

NYSEAM:CATX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	0	-71	-36	-57	5
12/31/2025	0	-65	-68	-59	8
12/31/2024	1	-53	-66	-41	7
6/30/2024	1	-52	-25	-14	N/A
3/31/2024	2	-50	-23	-13	N/A
12/31/2023	1	-37	-38	-37	N/A
9/30/2023	1	-20	-33	-32	N/A
6/30/2023	1	-13	-25	-24	N/A
3/31/2023	3	-6	-19	-19	N/A
12/31/2022	5	-8	-11	-10	N/A
9/30/2022	10	-9	-8	-7	N/A
6/30/2022	N/A	-6	-8	-8	N/A
3/31/2022	11	-6	-6	-6	N/A
12/31/2021	11	-6	-5	-5	N/A
9/30/2021	10	-5	-5	-5	N/A
6/30/2021	10	-3	-3	-3	N/A
3/31/2021	10	-4	-3	-3	N/A
12/31/2020	10	-3	-3	-3	N/A
9/30/2020	10	-3	-4	-3	N/A
6/30/2020	10	-3	-4	-4	N/A
3/31/2020	9	-3	-4	-4	N/A
12/31/2019	8	-4	-5	-4	N/A
9/30/2019	8	-4	-5	-4	N/A
6/30/2019	7	-5	-5	-5	N/A
3/31/2019	7	-6	-6	-6	N/A
12/31/2018	7	-7	-6	-5	N/A
9/30/2018	6	-7	-6	-6	N/A
6/30/2018	6	-7	-6	-6	N/A
3/31/2018	6	-6	N/A	-5	N/A
12/31/2017	5	-6	N/A	-6	N/A
9/30/2017	5	-6	N/A	-6	N/A
6/30/2017	5	-6	N/A	-6	N/A
3/31/2017	5	-6	N/A	-6	N/A
12/31/2016	4	-5	N/A	-5	N/A
9/30/2016	5	-5	N/A	-4	N/A
6/30/2016	5	-5	N/A	-4	N/A
3/31/2016	5	-5	N/A	-3	N/A
12/31/2015	5	-4	N/A	-4	N/A
9/30/2015	5	-4	N/A	-3	N/A
6/30/2015	5	-4	N/A	-4	N/A
3/31/2015	4	-4	N/A	-4	N/A
12/31/2014	4	-5	N/A	-3	N/A
9/30/2014	4	-5	N/A	-3	N/A
6/30/2014	4	-7	N/A	-3	N/A
3/31/2014	4	-6	N/A	-3	N/A
12/31/2013	5	-5	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CATX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CATX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CATX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CATX ( 79.6% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CATX ( 79.6% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CATX devrait être élevé dans 3 ans

Perspective Therapeutics Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates increase by 51%, EPS downgraded

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Consensus revenue estimates increase by 51%, EPS downgraded

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

CFO & Co-Principal Financial Officer recently bought US$177k worth of stock

CEO & Director recently bought US$117k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought US$140k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Second quarter 2023 earnings released

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Chairperson of the Board exercised options to buy US$129k worth of stock.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

Isoray, Inc. to Report Q4, 2022 Results on Sep 28, 2022

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance